Unknown

Dataset Information

Mapping the genealogy of medical device predicates in the United States.


ABSTRACT:

Background

In the United States, medical devices are regulated and subject to review by the Food and Drug Administration (FDA) before they can be marketed. Low-to-medium risk novel medical devices can be reviewed under the De Novo umbrella before they can proceed to market, and this process can be fairly cumbersome, expensive, and time-consuming. An alternate faster and less-expensive pathway to going to market is the 510(k) pathway. In this approach, if the device can be shown to be substantially equivalent in safety and effectiveness to a pre-existing FDA-approved marketed device (or "predicates"), it can be cleared to market. Due to the possibility of daisy-chaining predicate devices, it can very quickly be difficult to unravel the logic and justification of how a particular med

SUBMITTER: Pai DB 

PROVIDER: S-EPMC8496833 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature